| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978107 | Brachytherapy | 2007 | 9 Pages |
Abstract
Interstitial 192Ir-HDR implant boost with break and EBRT boost without break yield similar results. Acute skin toxicity is reduced with BT boost but long-term morbidity and QOL are identical. BT boost is most beneficial in early stage tumors but the advantage of BT seems to be limited due to its invasiveness, doctor dependence, and logistic circumstances.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Christoph Oehler-Jänne, Burkhardt Seifert, Urs M. Lütolf, Gabriela Studer, Christoph Glanzmann, I. Frank Ciernik,